The clonal proliferation of neoplastic plasma cells and the overproduction of monoclonal immunoglobulins promote the multi-system consequences of multiple myeloma (MM), which confers a high-risk of cardiac complications [1]. These complications are caused by epidemiological factors (e.g., advanced age at disease onset), intrinsic disease characteristics (e.g. cardiac amyloidosis [CA]), and treatment-related toxicities [2]. Early recognition of cardiac dysfunction in patients with MM may affect treatment selection and long-term prognosis regardless of age and is particularly important for light chain (AL) CA that represents a medical emergency [2].
